These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8024259)

  • 1. Levodopa: rational and irrational pharmacology.
    Nutt JG
    Ann Neurol; 1994 Jul; 36(1):4-5. PubMed ID: 8024259
    [No Abstract]   [Full Text] [Related]  

  • 2. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 3. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on antiparkinsonian agents.
    Weiner M
    Geriatrics; 1982 Sep; 37(9):81-4, 89-91. PubMed ID: 6125455
    [No Abstract]   [Full Text] [Related]  

  • 8. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 9. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
    Broussolle E
    Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current problems of drug treatment of Parkinson disease].
    Kuran W
    Neurol Neurochir Pol; 1980; 14(4):427-35. PubMed ID: 7412998
    [No Abstract]   [Full Text] [Related]  

  • 13. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 14. [Motor complications in Parkinson disease, in patients undergoing levodopa therapy].
    García de Yébenes J; García Urra D; Vázquez A
    Neurologia; 1989; 4(1):1-3. PubMed ID: 2631800
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 18. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC; Macnamara L; Hasoon M; Vassallo M; Ross I
    Parkinsonism Relat Disord; 2006 Dec; 12(8):499-505. PubMed ID: 16935018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.